PP1420

Name of Study:

The full title for PP1420 is “A double-blind, randomised, placebo-controlled dose escalation study to assess the safety, tolerability and efficacy of single and multiple doses of PP1420 in healthy subjects”.

What does the study involve?

Pancreatic polypeptide (PP) is a naturally occurring substance found in the blood of healthy people. It is released after meals and decreases appetite in healthy people. PP1420 is a long-acting artificial version (an “analogue”) of PP that is being developed as a treatment for obesity. PP1420 has previously been given to humans in single doses up to 8 mg and no concerns about the safety and tolerability were found. This study is designed to test the safety and tolerability of PP1420 in single doses up to 64 mg.

Expenses of up to £100 per study day visit will be paid.

Who are we looking for?

You must be:

  • male
  • aged 18-50,
  • have a BMI (body mass index) of between 25-35 (find out your BMI here.)
  • a non-smoker.

How can I find more?

For more information on what this study involves, please email PP1420@imperial.ac.uk or call 020 3313 8082.

PP1420